Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients

Conclusions In conclusion, 12-month treatment with liraglutide in add-on to on-going hypoglycemic therapy significantly ameliorates all major CVD risk factors and reduces cardiometabolic risk, as estimated by VAI values.

http://link.springer.com/10.1007/s40618-014-0163-9

Source: Journal of Endocrinological Investigation - January 1, 2015 Category: Endocrinology Source Type: research